Related Experiment Video

Updated: Jun 28, 2026

Myeloid Innate Signaling Pathway Regulation by MALT1 Paracaspase Activity
07:09

Myeloid Innate Signaling Pathway Regulation by MALT1 Paracaspase Activity

Published on: January 7, 2019

Triptolide inhibits amyloid-beta1-42-induced TNF-alpha and IL-1beta production in cultured rat microglia

Jian Jiao1, Bing Xue, Lei Zhang

  • 1Neuroscience Research Institute and Department of Neurobiology, Peking University, Key Laboratory for Neuroscience of the Ministry of Education, 38 Xueyuan Road, Beijing 100083, PR China.

Journal of Neuroimmunology
|November 14, 2008
PubMed

Insights

Oligomeric amyloid-beta (Abeta1-42) significantly elevates inflammatory markers in microglia, suggesting a key role in Alzheimer's disease (AD) neuroinflammation. Triptolide effectively reduces these inflammatory responses, indicating potential therapeutic benefits for AD.

Area of Science:

  • Neuroscience
  • Immunology
  • Pharmacology

Background:

  • Microglia are key immune cells in the brain, critically involved in neuroinflammation.
  • Neuroinflammation, particularly mediated by microglia, is a significant factor in Alzheimer's disease (AD) pathogenesis.
  • Targeting microglial activation presents a potential therapeutic strategy for AD.

Purpose of the Study:

  • To investigate the differential effects of various amyloid-beta (Abeta) forms on microglial activation.
  • To evaluate the efficacy of triptolide, an anti-inflammatory agent, in modulating Abeta-induced microglial responses.
  • To explore the potential of inhibiting microglial pro-inflammatory cytokine production for AD treatment.

Main Methods:

  • Primary rat microglial cultures were utilized to assess cellular responses.
  • Exposure to monomeric, fibrillar, and oligomeric forms of Abeta1-42.
  • Measurement of pro-inflammatory cytokines, specifically tumor necrosis factor-alpha (TNF-alpha) and interleukin-1beta (IL-1beta).
  • Pretreatment with triptolide to evaluate its anti-inflammatory effects.

Main Results:

  • Oligomeric Abeta1-42 significantly increased the levels of TNF-alpha and IL-1beta compared to monomeric and fibrillar forms.
  • Pretreatment with triptolide markedly reduced the elevation of TNF-alpha and IL-1beta induced by oligomeric Abeta1-42.
  • These findings highlight the potent inflammatory capacity of oligomeric Abeta and the suppressive effect of triptolide.

Conclusions:

  • Oligomeric Abeta1-42 is a potent inducer of microglial pro-inflammatory cytokine production, playing a crucial role in AD-associated neuroinflammation.
  • Triptolide demonstrates significant potential in suppressing microglial activation and the release of inflammatory mediators.
  • Targeting oligomeric Abeta-induced microglial responses with agents like triptolide may offer a neuroprotective strategy for Alzheimer's disease.

More Related Videos

Isolation of Cortical Microglia with Preserved Immunophenotype and Functionality From Murine Neonates09:12

Isolation of Cortical Microglia with Preserved Immunophenotype and Functionality From Murine Neonates

Published on: January 30, 2014

Primary Microglia Isolation from Mixed Glial Cell Cultures of Neonatal Rat Brain Tissue10:20

Primary Microglia Isolation from Mixed Glial Cell Cultures of Neonatal Rat Brain Tissue

Published on: August 15, 2012

Related Concept Videos

Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
Antiprotozoal Agents01:21

Antiprotozoal Agents

Leishmaniasis is a widespread parasitic disease caused by several Leishmania species. It affects millions of people each year and remains a major public health problem in endemic regions. First-line treatment relies on pentavalent antimonials, including meglumine antimoniate and sodium stibogluconate. Even so, how these drugs work has not been fully clear, especially their interaction with parasite-specific biochemical pathways. One key target is trypanothione reductase (TR), an enzyme that...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
T Cell Types and Functions01:24

T Cell Types and Functions

When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...